Introducing IPC Pitch Judges at RESI JPM San Francisco

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

The Life Science Nation (LSN)‘s RESI JPM San Francisco 2023 is only less than two weeks away! For this conference, the Innovator’s Pitch Challenge (IPC) is especially popular and we are featuring over 50 presenting startups from across 14 sessions, each focusing on a specific sector/subsector. The LSN team has been very busy recruiting for active investors and industry experts to join the pitch judge panels. The investor and industry experts were invited to sessions based on their experience, investment interest and expertise. The judges will listen to 4-minutes of company pitches and have 8-9 minutes to engage in Q&A and provide feedback to the pitching companies.

Below is a partial list of IPC pitch judges at RESI San Francisco. Sign up for RESI SF 2023 to join them!


Brent Ahrens
General Partner
Canaan Partners

Ivneet Bhullar
Principal
Fusion Fund

Jian Cao
Sr Research Manager & Technical Fellow
Medtronic

Evan Caplan
Principal
OrbiMed Advisors LLC

Dipty Desai
Co-Chair, TiE Global Health
TiE Angels

Karen Drexler
Life Science Councils
Astia Angels

Gary Gershony
Partner
BayMed Venture Partners

Anton Gopka
CEO and General Partner
ATEM Capital

Linda Greub
General Partner
Avestria Ventures

Michael Hansen
Innovation Scouting Director – North America
Eppendorf

Dave Hood
West Coast Outreach
Medical Technology Enterprise Consortium (MTEC)

Melya Hughes Crameri
Managing Director
Awen GmbH

Tomoko Ishikura
Partner
Kicker Ventures

Elizabeth Kayser
Member
Barrington Angels

Moazam Khan
Business Advisor
Velocity Incubator

John Kim
Principal
Aphelion Capital, LLC

Kristin King
Member
Boston Harbor Angels

Bill Mantzoutsos
Angel Investor

Linda Maxwell
Director
Biomedical Zone

James Mayer
Senior Manager, Investment & Venture Services
Centre for Aging + Brain Health Innovation (CABHI)

Matthew McNamara
Chief Investment Officer
Horizon 3 Biotech

Brian Meshkin
Managing Partner
Profound Ventures

Ting Pau Oei
Venture Partner
Gore Range Capital

Daniel Parera
Partner
Kurma Partners

Diana Saraceni
Founder, Managing Director
Panakes Partners

Eran Steinberg
Imaging Arts

Lu Wang
Foothill Ventures

Kyoko Watanabe
Managing Director
DEFTA Partners

Tad Weems
Managing Director
Agilent Technologies

Travis Whitfill
Partner
Bios Partners

RESI-SF-2023-Banner-1100-wide

Partnering At RESI JPM San Francisco

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Partnering opened for RESI JPM San Francisco on December 19, and the RESI partnering platform is a hive of activity. The primary goal of RESI has always been to foster conversations between companies, investors and strategic partners, and service providers who can all work together to bring the next generation of healthcare technology to market. As a hybrid conference, we are seeing the number of meetings booked increase steadily. The hybrid format proves to be one that works for the RESI community, as we see meetings being scheduled for both the in-person conference and still seeing about half of the meetings so far scheduled virtually. For those who are still thinking of registering, there’s still time! You can still register for both in-person on Tuesday, January 10 at the Marines’ Memorial Club & Hotel (hurry, this is almost SOLD OUT), and Virtual January 11-12. In our experience, over 50% of the meetings are booked within the week before the conference, so there is still a lot of time left to book plenty of meetings!

RESI San Francisco is LSN’s largest event of the year – with over 400 investors already registered, and more registering every day, start the new year off right by catapulting your fundraising campaign forward with all the networking opportunities available at RESI and JPM.

RESI-SF-2023-Banner-1100-wide

Hot Investor Mandate: Venture Builder and Investor Invests up to $1M Globally in Pre-Seed and Seed Stage Companies

The venture fund and venture builder invests in multiple healthcare sectors including therapeutics and synthetic biology, life science tools, IVD, medical devices, digital health and microbiome. The firm invests in pre-seed/seed stage companies with some proof of concept, looking to be the first institutional money in. The firm will invest globally, and looks to invest between $400k-1M. As an igniter, the firm takes a very active role in company formation, development and executive management.

The firm is interested in therapeutics, life science tools, medical devices, synthetic biology, and microbiome related technologies. Within these areas, anything relevant will be considered, including digital health and in vitro diagnostics. The firm is agnostic to indication.

The firm only invests in the first institutional capital round. The firm can invest, or act as a co-founder, depending on the needs of the company/founding team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: California Based Venture Fund Investing $1-15M in Precision Medicine, Medical Devices and AI-Enabled Services

The investor is a Venture Capital firm based in San Francisco California. The firm is interested in making equity investments into early stage companies with investments ranging from $1M to $15 million per company, depending on the companies needs and stage of development. The firm is currently seeking investment opportunities throughout the United States.

The firm is looking for companies operating in Precision medicine, MedTech and medicine at the edge, AI-enabled services such as drug discovery and clinical trial support, and synthetic biology with a software component. The firm is entirely opportunistic in terms of indication and will consider companies at all stages of development.

The firm is looking for privately held companies with strong management teams. The firm is able to provide entrepreneurs with a 200-person advisory network and bring deep operational expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Studio Interested in Digital Health Companies Entering the US Market, Investing Capital and Strategic Assistance

The venture studio located in New York City. In addition to its core venture creation function, the group in early-stage digital health companies looking to enter the US market for which its platform can offer catalytic growth. In addition to providing capital, the firm assists companies with regulatory approval and commercialization in the US, through their unique company creation partnership with a large health system.

The firm invests across the spectrum of digital health, with a particular focus on companies developing AI-based technologies, virtual care and other health-related technologies.

The firm generally seeks to work hand-in-hand with management to drive value creation and assist portfolio companies with US market entry. They work with pre-revenue companies, as well as with those that are more advanced internationally and looking to enter the US market. The firm considers both minority investments and acquisitions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Firm Focused on Pediatric Indications Investing in All Sectors in Companies that Have Some Validation Data

The seed-stage VC fund headquartered on the West Coast and founded in 2020. The firm focuses exclusively on pediatrics, and will invest in all sectors. The firm invests out of an evergreen fund, and looks to invest $500k-1M in US-based companies that have raised some non-dilutive capital. Many of the firm’s portfolio companies come from The firm’s connections with incubators and universities. For stage of development, the firm prefers for device companies to have hit initial regulatory milestones, and for diagnostics and digital health companies to have had a pilot study. For therapeutics, the firm has a strong interest in repurposed drugs.

While the firm is agnostic to sector and subsector, they will only invest in companies whose primary indication is related to pediatrics, including orphan indications.

The firm is an active investor, and likes to play a role in helping the company advance. They tend to co-invest, and generally do not require a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Watershed Informatics Exhibit at RESI JPM San Francisco

Madeline-Kelly
Madeline Kelly
Interview with Madeline Kelly, Head of Sales, Watershed Informatics

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Watershed Informatics’ intuitive Data Lab platform empowers our clients to design, execute, and iterate their own sequencing analyses, shortening time between iterations and enabling more efficient and effective experimentation. They expedite and multiply the development of targeted, breakthrough therapies and diagnostics. Watershed returns to RESI this January as an exhibitor. In the following interview, Watershed’s Head of Sales, Madeline Kelly, provides insight on how Watershed came to be, their technology, team, and target customer.

Caiti Dolegowski (CD): Please introduce us to Watershed. Tell us about your technology and platform.

Madeline Kelly (MK): Watershed Informatics is the first fully verticalized bio-IT platform. Our Cloud Data Lab enables life sciences organizations of any size to perform mission-critical bioinformatics analyses (such as bulk, single-cell, and spatial transcriptomics; WGS, proteomics, protein folding, AI/ML etc.) at an order of magnitude less cost and complexity than existing solutions. With purpose-built infrastructure specifically optimized for catalyzing the life sciences development pipeline, our product enables biologists to analyze their own data and bioinformaticians to rapidly prototype and deploy bespoke analytic workflows across an organization.

CD: Tell us about Watershed’s team?

MK: We are a team of expert bioinformaticians, software engineers, and biologists inspired by one mission: to enable all scientists – regardless of their programming capabilities – to leverage multi-modal data for building better drugs faster.

CD: Watershed’s Cloud Data lab can be traced to a conversation between co-founders, Jonathan Wang and Mark Kalinich. What was the conversation and how do they complement each other?

MK: Jonathan and Mark have been friends since their first day of MIT – they were actually next-door neighbors freshman year! As a software engineer, Jonathan has always been fascinated by high-performance computational infrastructure. He co-founded an algorithmic trading firm while still a student at MIT. While there, he perfected the tech stack required to democratize access to petabyte-scale ML infrastructure for software engineers and financial researchers alike. Mark is a Harvard-trained physician-scientist with nearly 15 years of translational research experience across diagnostics and therapeutics development. His mission is to improve the lives of patients by developing and deploying the enabling technologies required to bring therapeutics out of the laboratory and into the clinic. Their expertise and passions directly intersect at the problem Watershed solves: uncorking the bottleneck for biotech and pharma’s data-intensive research efforts.

CD: Who is your target customer? And what are the different offerings you provide your clients?

MK: Our target customers want to successfully and efficiently analyze their big biology data (most often -omics, but also protein folding and high content imaging) without the massive overhead currently required. (To learn more about what we mean by overhead, download our white paper). With our no-code / low-code / high-code interoperability, our platform is useful to biologists and bioinformaticians alike.

CD: Do you have a process for assessing your clients’ needs? How does that work?

MK: Watershed employs a highly consultative sales and onboarding process. We thoroughly assess the needs of our customers by learning about their workflow, analysis, and visualization needs. Our team of bioinformaticians are ready to assist our clients from day 1.

CD: Could you give us examples of current Watershed clients and how they’ve utilized your informatics?

MK: Some of our clients include SalioGen, Cellino, SynDevRx, Rejuvenate Bio, Rarebase, Revitope, and a few stealth biotech startups. Our customers’ most common request is processing next-generation sequencing data across a variety of workflows (bulk, single-cell, and spatial RNAseq; whole genome and whole exome sequencing, bulk and single-cell ATACseq, immune repertoire sequencing, CRISPR-based analyses, custom sequencing libraries, etc) and technologies (Illumina, ONT, PacBio). In addition to other data-intensive workflows (metabolomics, proteomics, high-content imaging, protein-folding) and publicly available datasets (TCGA, CCLE, GTex, UKBB), our platform has been purpose-built to overlay advanced AI/ML techniques on these data, including deep learning, generative AI, structure-based learning models, and NLP, among others.

CD: We’re thrilled to Watershed back as an exhibitor at RESI JPM San Francisco! What would you like our RESI attendees to know about Watershed

MK: We are excited to join RESI JPM San Francisco as first-time attendees! We want to meet as many of you as possible, so swing by our booth to check out our platform and enter for a chance to win 1 free month of Watershed’s Cloud Data Lab (details available at the conference). See you there!

RESI-SF-2023-Banner-1100-wide